Bugs against chlamydia

Synthetic biology company Prokarium Ltd. is creating oral vaccines based on a bacterial system that produces a wider range of antigens and fewer side effects than injectables. With its goal to produce the first vaccine for chlamydia, the company is banking on the notion that the HPV vaccine has increased public acceptance for immunizing against STDs.

Prokarium CEO Ted Fjällman told BioCentury a key advantage of the company's technology is that it can create antigens from conformationally complex membrane proteins that have thwarted conventional technologies. ...